YARGESA 100 mg, hard capsule 84 capsules
Active ingredients: Miglustat
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule84 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- YARGESA 100 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 84 plaquette(s) thermoformée(s) PVC polychlortrifluoroéthylène aluminium de 1 gélule(s)
- Marketing authorisation holder
- PIRAMAL CRITICAL CARE (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Oct 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68836272CIP73018233CIP133400930182338Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| MIGLUSTATgélule | 100 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.